{
    "clinical_study": {
        "@rank": "33",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04330586"
        },
        "id_info": {
            "org_study_id": "KUMC-COVID-19",
            "nct_id": "NCT04330586"
        },
        "brief_title": "A Trial of Ciclesonide in Adults With Mild COVID-19",
        "official_title": "A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea University Guro Hospital",
                "agency_class": "Other"
            }
        },
        "source": "Korea University Guro Hospital",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "According to In vitro studies, ciclesonide showed good antiviral activity against severe\n      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for\n      the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical\n      trial to evaluate the antiviral effect on the reduction of viral load in patients with\n      COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination\n      with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients\n      with mild COVID-19."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "June 30, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of ciclesonide, ciclesonide plus hydroxychloroquine or control arm",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Rate of SARS-CoV-2 eradication at day 14 from study enrollment",
            "time_frame": "Hospital day 14",
            "description": "Viral load"
        },
        "secondary_outcome": [
            {
                "measure": "Rate of SARS-CoV-2 eradication at day 7 from study enrollment",
                "time_frame": "Hospital day 7",
                "description": "Viral load"
            },
            {
                "measure": "Time to SARS-CoV-2 eradication (days)",
                "time_frame": "Hospital day 1, 4, 7, 10, 14, 21",
                "description": "Viral load"
            },
            {
                "measure": "Viral load area-under-the-curve (AUC) reduction versus control",
                "time_frame": "Hospital day 1, 4, 7, 10, 14, 21",
                "description": "Viral load change"
            },
            {
                "measure": "Time to clinical improvement (days)",
                "time_frame": "Up to 28 days",
                "description": "Resolution of all systemic and respiratory symptoms for \u22652 consecutive days"
            },
            {
                "measure": "Proportion of clinical failure",
                "time_frame": "Up to 28 days",
                "description": "ICU admission, mechanical ventilation or death"
            }
        ],
        "other_outcome": {
            "measure": "Safety and tolerability of study drug",
            "time_frame": "Up to 28 days",
            "description": "Number of adverse events, proportion of early discontinuance"
        },
        "number_of_arms": "3",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "141"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "Ciclesonide",
                "arm_group_type": "Experimental",
                "description": "Ciclesonide 320ug oral inhalation q12h for 14 days"
            },
            {
                "arm_group_label": "Ciclesonide plus hydroxychloroquine",
                "arm_group_type": "Active Comparator",
                "description": "Ciclesonide 320ug oral inhalation q12h for 14 days\nHydroxychloroquine 400mg QD for 10 days"
            },
            {
                "arm_group_label": "Control",
                "arm_group_type": "No Intervention",
                "description": "No ciclesonide and hydroxychloroquine"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Ciclesonide Metered Dose Inhaler [Alvesco]",
                "description": "Ciclesonide 320ug oral inhalation q12h for 14 days",
                "arm_group_label": [
                    "Ciclesonide",
                    "Ciclesonide plus hydroxychloroquine"
                ]
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Hydroxychloroquine",
                "description": "Hydroxychloroquine 400mg QD for 10 days",
                "arm_group_label": "Ciclesonide plus hydroxychloroquine"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with mild COVID-19 (NEWS scoring system 0-4)\n\n          -  Patient within 7 days from symptom onset or Patient within 48 hous after laboratory\n             diagnosis (SARS-CoV-2 RT-PCR)\n\n        Exclusion Criteria:\n\n          -  Unable to take oral medication\n\n          -  Unable to use inhaler\n\n          -  Pregnancy or breast feeding\n\n          -  Immunocompromising conditions\n\n          -  Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min\n\n          -  Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit\n\n          -  Asthma or chronic obstructive lung disease"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "80 Years",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Joon Young Song, MD, PhD",
            "phone": "82-2-2626-3052",
            "email": "infection@korea.ac.kr"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 31, 2020",
        "study_first_submitted_qc": "March 31, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 1, 2020"
        },
        "last_update_submitted": "March 31, 2020",
        "last_update_submitted_qc": "March 31, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 1, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Korea University Guro Hospital",
            "investigator_full_name": "Woo Joo Kim",
            "investigator_title": "Professor"
        },
        "keyword": [
            "SARS-CoV-2",
            "Ciclesonide",
            "Hydroxychloroquine",
            "Viral load",
            "Coronavirus"
        ],
        "intervention_browse": {
            "mesh_term": [
                "Ciclesonide",
                "Hydroxychloroquine"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}